View abstract

This abstract is assigned to sessions
Presentation preference Oral presentation
TitleUveitis following the BNT162b2 mRNA vaccination against SARS-CoV-2 infection
PurposeTo describe the occurrence of uveitis shortly following the administration of BNT162b2 mRNA SARS-CoV-2 vaccination.
MethodsThis is a multicenter, retrospective study in which patients were identified and the diagnosis supported by the classification of the World Health Organization Adverse Drug Terminology and the Naranjo criteria with vaccine related-uveitis.
ResultsTwenty-one patients (23 eyes) with a mean age of 51.3 years (range, 23-78 years) were included. Eight of these 21 patients had a known history of uveitis, with a median time from prior to the current uveitis attack of 1 year (range, 0.5-15 years). There were 21 cases of anterior uveitis, including two with bilateral inflammation, and all but 3 presented as mild to moderate disease. Eight of these case presented after the first vaccine dose, whereas 13 presented following the second. Two patients developed multiple evanescent white dot syndrome (MEWDS) following the second vaccine dose. Mean time between vaccination to uveitis onset was 7.5 ± 7.3 days (range, 1-30 days). At final follow-up, which ranged from 30 to 126 weeks, complete resolution was achieved in all but two eyes, which showed significant improvement. One case of severe anterior uveitis developed vitritis and macular edema following their second vaccine dose, and which completely resolved following an intravitreal dexamethasone injection.
ConclusionAdministration of the BNT162b2 mRNA vaccine can be followed by the development of uveitis. As with other vaccines, the most common complication was mild to moderate, anterior uveitis. While less frequent, MEWDS can also occur.

Conflict of interestNo
Authors 1
Initials of first name(s)Z
DepartmentDivision of Ophthalmology, Tel Aviv Medical Center
CityTel Aviv